|
|
Volumn 53, Issue 18, 1996, Pages 2206-2214
|
|
Considerations in the formulary selection of hydroxymethylglutaryl- coenzyme A reductase inhibitors
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOSPORIN;
ERYTHROMYCIN;
FLUINDOSTATIN;
GEMFIBROZIL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MEVINOLIN;
NICOTINIC ACID;
PRAVASTATIN;
SIMVASTATIN;
CLINICAL TRIAL;
CORONARY ARTERY DISEASE;
COST EFFECTIVENESS ANALYSIS;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MECHANISM;
DRUG POTENTIATION;
DRUG SAFETY;
GASTROINTESTINAL SYMPTOM;
HEADACHE;
HUMAN;
HYPERLIPIDEMIA;
LIVER TOXICITY;
MYOPATHY;
NOTE;
PRIORITY JOURNAL;
RASH;
|
|
EID: 0029787479
PISSN: 10792082
EISSN: None
Source Type: Journal
DOI: 10.1093/ajhp/53.18.2206 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
